Literature DB >> 16522342

TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue.

Marta Barrachina1, Esther Castaño, Isidro Ferrer.   

Abstract

The brain tissue obtained after death is subjected to several circumstances that can affect RNA integrity. The present study has been directed to reveal possible pitfalls and to control RNA normalization in post-mortem samples in order to recognize the limitations and minimize errors when using TaqMan PCR technology. This has been carried out in samples of the frontal cortex in a series of control and diseased cases covering Parkinson's disease, dementia with Lewy bodies pure form and common form, and Alzheimer's disease. Special attention has been paid to the value of the agonal state, post-mortem delay and pH of the nervous tissue as approximate predictors of the quality of RNA, as well as to the use of the Bioanalyzer to confirm RNA preservation. In addition, since possible disease-modified mRNAs have to be normalized with ideal unaltered RNAs, TaqMan human endogenous control plates have been used to determine the endogenous control most appropriate for the study. beta-glucuronidase (GUS) and beta-actin were good endogenous controls because their expression levels showed a small variation across a representative number of control and pathological cases. RNA stability was also analysed in a paradigm mimicking cumulative delay in tissue processing. GUS mRNA levels were not modified although beta-actin mRNA levels showed degradation at 22 h. Finally, the control of RNA degradation for the normalization of genes of interest was also tested. mRNA expression levels for superoxide dismutase 1 (SOD1) and metalloproteinase domain 22 (ADAM22) were examined at several artificial post-mortem times, and their expression levels compared with those for putative controls beta-actin and GUS. In our paradigm, the expressions of SOD1 and ADAM22 were apparently not modified when normalized with beta-actin. Yet their expression levels were reduced with post-mortem delay when values were normalized with GUS. Taken together, these observations point to practical consequences in TaqMan PCR studies. Short post-mortem delays and acceptable pH of the brain are not sufficient to rule out RNA degradation. The selection of adequate endogenous controls is pivotal in the study. beta-actin and GUS are found to be good endogenous controls in these pathologies, although GUS but not beta-actin expression levels are preserved in samples with long post-mortem delay.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522342     DOI: 10.1016/j.neuint.2006.01.018

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  32 in total

Review 1.  The relationship between encephalitis lethargica and influenza: a critical analysis.

Authors:  Sherman McCall; Joel A Vilensky; Sid Gilman; Jeffery K Taubenberger
Journal:  J Neurovirol       Date:  2008-05       Impact factor: 2.643

2.  The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study.

Authors:  David Meyronet; Aline Dorey; Patrick Massoma; Catherine Rey; Eudeline Alix; Karen Silva; Corinne Perrin; Isabelle Quadrio; Armand Perret-Liaudet; Nathalie Streichenberger; Nicole Thomasset; Jérôme Honnorat; Thomas Arzberger; Hans Kretzschmar
Journal:  J Neural Transm (Vienna)       Date:  2015-05-16       Impact factor: 3.575

3.  Human postmortem tissue: what quality markers matter?

Authors:  Ana D Stan; Subroto Ghose; Xue-Min Gao; Rosalinda C Roberts; Kelly Lewis-Amezcua; Kimmo J Hatanpaa; Carol A Tamminga
Journal:  Brain Res       Date:  2006-10-12       Impact factor: 3.252

4.  Validation of adequate endogenous reference genes for reverse transcription-qPCR studies in human post-mortem brain tissue of SIDS cases.

Authors:  Noha El-Kashef; Iva Gomes; Katja Mercer-Chalmers-Bender; Peter M Schneider; Markus A Rothschild; Martin Juebner
Journal:  Forensic Sci Med Pathol       Date:  2015-10-05       Impact factor: 2.007

5.  Altered mechanisms of protein synthesis in frontal cortex in Alzheimer disease and a mouse model.

Authors:  Paula Garcia-Esparcia; Georgios Sideris-Lampretsas; Karina Hernandez-Ortega; Oriol Grau-Rivera; Theodoros Sklaviadis; Ellen Gelpi; Isidro Ferrer
Journal:  Am J Neurodegener Dis       Date:  2017-06-15

6.  Target genes of neuron-restrictive silencer factor are abnormally up-regulated in human myotilinopathy.

Authors:  Marta Barrachina; Jesús Moreno; Salvador Juvés; Dolores Moreno; Montse Olivé; Isidre Ferrer
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

7.  The alternative splicing of the apolipoprotein E gene is unperturbed in the brains of Alzheimer's disease patients.

Authors:  James D Mills; Pamela J Sheahan; Donna Lai; Jillian J Kril; Michael Janitz; Greg T Sutherland
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

8.  Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set.

Authors:  Winnie S Liang; Travis Dunckley; Thomas G Beach; Andrew Grover; Diego Mastroeni; Keri Ramsey; Richard J Caselli; Walter A Kukull; Daniel McKeel; John C Morris; Christine M Hulette; Donald Schmechel; Eric M Reiman; Joseph Rogers; Dietrich A Stephan
Journal:  Physiol Genomics       Date:  2008-02-12       Impact factor: 3.107

Review 9.  The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings.

Authors:  Maryam Shabihkhani; Gregory M Lucey; Bowen Wei; Sergey Mareninov; Jerry J Lou; Harry V Vinters; Elyse J Singer; Timothy F Cloughesy; William H Yong
Journal:  Clin Biochem       Date:  2014-01-12       Impact factor: 3.281

10.  Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology.

Authors:  Winnie S Liang; Travis Dunckley; Thomas G Beach; Andrew Grover; Diego Mastroeni; Keri Ramsey; Richard J Caselli; Walter A Kukull; Daniel McKeel; John C Morris; Christine M Hulette; Donald Schmechel; Eric M Reiman; Joseph Rogers; Dietrich A Stephan
Journal:  Neurobiol Aging       Date:  2008-06-24       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.